NCT04181931 (NeoconceptC) is a NA clinical trial of neo-TACE-HAIC+Surgery in Hepatocellular Carcinoma, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04181931?

NCT04181931 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04181931?

Interventions in NCT04181931: neo-TACE-HAIC+Surgery, Surgery alone.

What condition does NCT04181931 study?

NCT04181931 studies Hepatocellular Carcinoma, Portal Vein Thrombosis.

Is NCT04181931 still recruiting?

NCT04181931 is currently status unknown. Last updated 26 October 2020.

Last reviewed 2020-10-26 · How we verify

NCT04181931: NeoconceptC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neo-TACE-HAIC for PVTT-HCC

Status unknown NA Last updated 26 October 2020

What this trial tests

NA trial testing neo-TACE-HAIC+Surgery in Hepatocellular Carcinoma in 320 participants. Status unknown.

Timeline

16 December 2019

Primary endpoint
30 December 2022

30 December 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	320
Start date	16 December 2019
Primary completion	30 December 2022
Estimated completion	30 December 2024
Sites	2 locations across China

Drugs / interventions tested

neo-TACE-HAIC+Surgery
Surgery alone

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Portal Vein Thrombosis — all drugs for Portal Vein Thrombosis →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma or Portal Vein Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for treatments. Although BCLC (Barcelona clinical liver cancer) system recommend to palliative targeted treatment, the East Asian countries recommend to resection or transartery chemoembolization (TACE). Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate. Whether TACE-HAIC would improve survival for patients with PVTT is need to further to study. A randomized clinical trial compared neo-TACE-HAIC with surgery versus surgery alone is aimed to answer this question.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.
Kuemmerli C, Hess V, Dutkowski P, Sinz S, et al · · 2024 · cited 3× · PMID 38368862 · DOI 10.1159/000537887

Verify or expand the search:

Other trials of neo-TACE-HAIC+Surgery

Trials testing the same drug.

NCT04777942 — Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA) · NA · recruiting
NCT04424043 — Neo-TACE-HAIC for BCLC B Stage HCC · NA · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04181931 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 26 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04181931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing